Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Cell|September 20, 2024
Scientists' call to action: Microbes, planetary health, and the Sustainable Development GoalsThomas W Crowther, Rino Rappuoli, Cinzia Corinaldesi, et al.
Ecology|January 20, 2026
FracFeed: Global database of the fraction of feeding predatorsMark Novak, Paige Foust, Shannon Hennessey, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozolePeter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde|February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
Pageof 10